JP2023526024A5 - - Google Patents

Info

Publication number
JP2023526024A5
JP2023526024A5 JP2022568632A JP2022568632A JP2023526024A5 JP 2023526024 A5 JP2023526024 A5 JP 2023526024A5 JP 2022568632 A JP2022568632 A JP 2022568632A JP 2022568632 A JP2022568632 A JP 2022568632A JP 2023526024 A5 JP2023526024 A5 JP 2023526024A5
Authority
JP
Japan
Prior art keywords
composition
composition according
polypeptide
kit
kit according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031616 external-priority patent/WO2021231319A1/en
Publication of JP2023526024A publication Critical patent/JP2023526024A/ja
Publication of JP2023526024A5 publication Critical patent/JP2023526024A5/ja
Pending legal-status Critical Current

Links

JP2022568632A 2020-05-11 2021-05-10 Il-2融合ポリペプチド組成物ならびにその作製及び使用方法 Pending JP2023526024A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022860P 2020-05-11 2020-05-11
US63/022,860 2020-05-11
PCT/US2021/031616 WO2021231319A1 (en) 2020-05-11 2021-05-10 Il-2 fusion polypeptide compositions and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2023526024A JP2023526024A (ja) 2023-06-20
JP2023526024A5 true JP2023526024A5 (cg-RX-API-DMAC10.html) 2024-05-17

Family

ID=78524880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568632A Pending JP2023526024A (ja) 2020-05-11 2021-05-10 Il-2融合ポリペプチド組成物ならびにその作製及び使用方法

Country Status (12)

Country Link
US (1) US20210395325A1 (cg-RX-API-DMAC10.html)
EP (1) EP4149514A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023526024A (cg-RX-API-DMAC10.html)
KR (1) KR20230008759A (cg-RX-API-DMAC10.html)
CN (1) CN115867307A (cg-RX-API-DMAC10.html)
AU (1) AU2021269585A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022022869A2 (cg-RX-API-DMAC10.html)
CA (1) CA3172874A1 (cg-RX-API-DMAC10.html)
IL (1) IL298064A (cg-RX-API-DMAC10.html)
MX (1) MX2022014163A (cg-RX-API-DMAC10.html)
TW (1) TW202207971A (cg-RX-API-DMAC10.html)
WO (1) WO2021231319A1 (cg-RX-API-DMAC10.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156897B2 (en) * 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
EA202092926A3 (ru) * 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
EP3233920B1 (en) * 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
MA48763A (fr) * 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
US11273205B2 (en) * 2017-07-25 2022-03-15 Jiangsu Hengrui Medicine Co., Ltd. IL-15 protein complex pharmaceutical composition
WO2021074689A1 (en) * 2019-10-18 2021-04-22 Alkermes Pharma Ireland Limited Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors

Similar Documents

Publication Publication Date Title
JP2024099628A5 (cg-RX-API-DMAC10.html)
ES2409032T3 (es) Formulaciones liofilizadas de vwf recombinante
CN101272764B (zh) hFSH水制剂
ES2349472T3 (es) Formulación estable de interferón pegilado.
JP2025148550A5 (cg-RX-API-DMAC10.html)
JP2013500947A5 (cg-RX-API-DMAC10.html)
JP2021506922A5 (cg-RX-API-DMAC10.html)
JP2019509311A5 (cg-RX-API-DMAC10.html)
JP7263312B2 (ja) Il-15タンパク質複合体医薬組成物およびその使用
EP3156071A1 (en) Stable aqueous adalimumab preparation
JP2023523218A5 (cg-RX-API-DMAC10.html)
ES2224917T1 (es) Composiciones farmaceuticas de agente fibrinolitico.
JP2023539476A5 (cg-RX-API-DMAC10.html)
JP2021529763A5 (cg-RX-API-DMAC10.html)
EP4595950A2 (en) Annexin a1 n-terminal peptide formulations and methods
EP2119451A1 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
ZA202303162B (en) Compositions suitable for use in neonates
JP2022151814A5 (cg-RX-API-DMAC10.html)
ES2365832T3 (es) Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
US12564619B2 (en) Stable formulations of recombinant proteins
JP2021504349A5 (cg-RX-API-DMAC10.html)
KR20210107014A (ko) 페가스파가제의 동결건조 조성물
JPH04208228A (ja) インシュリン様成長因子iの乾燥製剤
US20230167162A1 (en) Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa
JP2023525565A5 (cg-RX-API-DMAC10.html)